Zimmer Biomet HoldingsFRA:ZIM +1.29%76 Net Margin % is 11.41% as of Mar. 2026, which is 58% above its 10-year median of 7.23. GuruFocus rates FRA:ZIM with a GF Score™ of 76/100 and a GF Value™ of €106.93 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 70.62% on this metric.
The historical rank and industry rank for Zimmer Biomet Holdings's Net Margin % or its related term are showing as below:
FRA:ZIM'
s Net Margin % Range Over the Past 10 Years
Min: -4.78 Med: 7.23 Max: 23.24
Current: 9.05
FRA:ZIM's Net Margin % is ranked better than 70.62% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:ZIM: 9.05
Zimmer Biomet Holdings (FRA:ZIM) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Zimmer Biomet Holdings Net Margin % Related Terms
Zimmer Biomet Holdings Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZIM vs PEN, GMED, STE: Net Margin % Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (FRA:ZIM) has a Net Margin % of 11.41% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Zimmer Biomet Holdings and its competitors. This is 58% above median its historical median of 7.23. According to the industry distribution chart, Zimmer Biomet Holdings ranks #240 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 29.4%.
Is Zimmer Biomet Holdings' Net Margin % too high?
Zimmer Biomet Holdings' current Net Margin % of 11.41% is 58% above median its 10-year median of 7.23. The Medical Devices & Instruments industry median Net Margin % is 2.07. Zimmer Biomet Holdings' value of 11.41% is 451.2% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #240 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Net Margin % compare to PEN and GMED?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #240 out of 817 companies for Net Margin %. This puts Zimmer Biomet Holdings in the upper half of its industry. The industry median Net Margin % is 2.07. Zimmer Biomet Holdings' value of 11.41% is 451.2% above this benchmark. While the company's 10-year median is 7.23 vs. the industry median of 2.07, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Net Margin % of 11.41% is 451.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Net Margin % is 11.41%, which is 58% above median its own 10-year median of 7.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Significantly Undervalued. The stock's GF Value™ is €106.93, compared to a current price of €76.80 — trading 28.2% below its estimated fair value. The current Net Margin % is 11.41%, which is 58% above median its 10-year median of 7.23 and 451.2% above the Medical Devices & Instruments industry median of 2.07. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current Net Margin % is 11.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of €76.80 is trading 28.2% below its estimated GF Value™ of €106.93.
GuruFocus considers Zimmer Biomet Holdings to be Significantly Undervalued.
Key valuation signals for FRA:ZIM:
Net Margin %: 11.41% (58% above median its 10-year median of 7.23)
GF Value™: €106.93 vs. price of €76.80 (28.2% below fair value)
Industry Position: 451.2% above the Medical Devices & Instruments median (#240 of 817)
No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score
Get the complete analysis for FRA:ZIM
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZIM has been successfully added to your 
